miscsubjectsAI governance
Evidence review

PT-141 for Muscle Loss: Evidence Review

· · 3 min read
bundle · json · system map · manifest

Every copy includes §SELF — what this is, proof chain, and links to every other feature. No context required.

§SELF — this page explains the system
## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `human_page` — **Human article page**
Rendered article with claims, sources, copy widgets, ask prompts.
- **article slug:** `pt-141-muscle-loss`
- **contains:** rendered article, copy widgets, claims, sources, ask prompts
- **how to use:** Use Copy for LLM or Copy system map — both paste without context.
- **read:** https://miscsubjects.com/a/pt-141-muscle-loss

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/pt-141-muscle-loss/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/pt-141-muscle-loss/bundle?format=markdown
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/pt-141-muscle-loss/prompts
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/pt-141-muscle-loss/topology

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

*Not medical advice. Tier-honest. Cite claim/source ids.*

What's breaking down

The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.

Why PT-141 might help you

  1. Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.

How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.

  • PT-141 → sexual / CNS arousal

What the evidence actually shows

This is a count of what is in this ledger — not a claim about all research worldwide.

  • Scientific sources catalogued (PubMed, trials, reviews): 1
  • Claims tagged human evidence: 2
  • Claims tagged preclinical (animal/lab): 0
  • Claims tagged anecdotal: 0
  • Reddit posts catalogued: 0
  • X posts catalogued: 0
  • Other anecdote sources (YouTube, Instagram, etc.): 0
  • Total sources in chain: 2

Logic: No social posts catalogued yet — we cannot report what people are saying on Reddit or X from this ledger.

Quantified confidence (this ledger): 0.27 / 1.00 — low — animal and anecdote heavy

Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.

What scientists say

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder (source s2)

Summary of phase 3 RECONNECT trial results.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

---

Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.

Explore this article's relationships

Muscle loss / sarcopenia · condition map

Connected articles

Where this sits in the evidence graph. Open the full interactive map for the whole neighborhood.

Full map →
RelatedPT-141: Brain-Level Arousal · 17 humanPT-141 (Bremelanotide) and Sexual Dysfunction in the Context of Blood… · 8 humanPT-141 for Chemotherapy Side Effects: Evidence on Sexual Arousal Pathw… · 3 humanPT-141 for Diabetic Neuropathy: Evidence-Graded Review · 3 human
Evidence · 2 sources · swipe →chain 11243c86b47e · verify chain · provenance
1 / 2
Evidence ledger 3 · tier-ranked · API
human
No scientific evidence or clinical research proves PT-141 increases muscle mass.
sources: s1
human
RECONNECT phase 3 trials showed statistically significant improvements in sexual desire and reduced distress versus placebo in women with HSDD.
sources: s2
mechanistic
PT-141 does not target muscle tissue regulatory processes for hypertrophy.
sources: s1
Model review1 contributions · 1 modelExpand the recursive review layer
1 / 1
grok/grok-4.3writer
redraft2026-06-30 01:13
PT-141 for Muscle Loss: Evidence Review · 3 claims · 2 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: Write a data-first, evidence-graded article: PT 141 for Muscle Loss
Slug: pt-141-muscle-loss
Audience: readers researching peptide evidence for this specific condition or drug cross.
Rules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.

ENRICHMENT BRIEF (binding section logic — one ## per compound):
{"voice":"enrichment","article_shape":"single_focus","condition":null,"condition_key":null,"primary_peptide":null,"peptides_in_scope":[{"id":"pt-141","name":"PT-141"}],"drugs_in_scope":[],"weight_sensitive":false,"stimulant_context":false,"breaking_down":{"section_title":"What's breaking down","degenerative_why":[],"degenerati
it output
{
  "slug": "pt-141-muscle-loss",
  "title": "PT-141 for Muscle Loss: Evidence Review",
  "body": "## What's breaking down\n\nMuscle loss, or sarcopenia in clinical terms, involves progressive decline in muscle mass, strength, and function. This happens when protein breakdown outpaces repair in muscle tissue. Layers include reduced anabolic signaling, inflammation, hormonal shifts, inactivity, and neural drive changes. Over time, fewer motor units fire effectively and satellite cells repair less efficiently. The result is frailty and reduced physical capacity. No direct peptide catalog entry replaces addressing these layers through established means.\n\n## Why PT-141 might help you\n\nPT-141 acts primarily on melanocortin receptors in the central nervous system to influence arousal pathways. The peptide chain focuses on the sexual / CNS arousal layer.\n\n1. Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\n\nIf reduced sexual activity or CNS drive contributes to lower overall movement and muscle maintenance, some discuss PT-141 in that context. This remains indirect. No data show direct effects on muscle protein synthesis or satellite cell activity. Any potential link would sit at the speculative tier for muscle loss specifically.\n\n## How these fit together\n\nSingle-compound focus —
dc496ee41e09e608
Machine verification: /api/articles/pt-141-muscle-loss/contributions

Latest from the journal

Most recent pieces, site-wide

All articles →
The Disc Stackposted 2026-07-24the-disc-stackHerniated Discposted 2026-07-24herniated-discDegenerative Disc Diseaseposted 2026-07-24degenerative-disc-diseaseBPC-157 vs NSAIDs: Repair or Suppress?posted 2026-07-24bpc-157-vs-nsaidsAgentKit: a post-mortem in advanceposted 2026-07-24what-agentkit-was

Related articles

Muscle loss / sarcopenia · condition map

Open evidence map →
PT-141: Brain-Level Arousalpt-141PT-141 and Benzodiazepine Withdrawal: A Data-First Evidence Reviewpt-141-benzo-withdrawalPT-141 and Benzodiazepines: Evidence Review on CNS Arousal Layerspt-141-benzodiazepinesPT-141 (Bremelanotide) and Sexual Dysfunction in the Context of Blood…pt-141-blood-pressure-medsPT-141 for Statin-Associated Cognitive Effects: Evidence Reviewpt-141-brain-fogPT-141 for Carpal Tunnel Syndrome: A Data-First Evidence Reviewpt-141-carpal-tunnel
Ask this article · 5 suggested prompts
topology · JSON · question graph

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (human tier): "No scientific evidence or clinical research proves PT-141 increases muscle mass."?
ask pt-141-muscle-loss claim c1 · paste includes §SELF
What does the ledger say about this (human tier): "RECONNECT phase 3 trials showed statistically significant improvements in sexual desire and reduced distress versus placebo in women with HS…"?
ask pt-141-muscle-loss claim c2 · paste includes §SELF
What does the ledger say about this (mechanistic tier): "PT-141 does not target muscle tissue regulatory processes for hypertrophy."?
ask pt-141-muscle-loss claim c3 · paste includes §SELF
For my medical situation, what can you answer from your catalogue about PT-141 for Muscle Loss: Evidence Review — and what would you need me to tell you first?
ask pt-141-muscle-loss condition gaps · paste includes §SELF
What good and bad outcomes are documented for PT-141 for Muscle Loss: Evidence Review (studies vs anecdotes)?
ask pt-141-muscle-loss good bad experiences · paste includes §SELF
Add your experience or question
Think this article is wrong?
Dispute this article in Claim Audit →